AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04667403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: In addition to his standard follow-up, the patient benefits from a home follow-up of his pain for 6 months from his inclusion in the study.~The patient has to log on via the application, every week. to fill in the questionnaire to evaluate the pain over the past week.~The questionnaire consists of 4 questions to which the patient answers using a numerical scale from 0 to 10.~If the patient's pain is not controlled, the patient can log on in emergency mode as many times as he or she deems necessary.~A nurse path coordinator will be informed of each connection. Depending on the type of alert received, she may initiate a telephone consultation with the oncologist or pain specialist:~* If necessary within 24 hours of the connection if it is a weekly connection,~* Systematic within 3 hours if it is an emergency connection or if the data entered at the time of the weekly connection requires medical intervention.
Study NCT05111132 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluid challenge (cristalloïd, NaCl 0,9%)
Description: A fluid challenge according to group will be administrated by infusion pump
Study NCT05252533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: This study does not provide dosing instructions for ustekinumab but will engage participants who have been treated with ustekinumab by their corresponding HCPs independent of this study.
Study NCT05550103 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.
Study NCT05550103 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
Study NCT05550103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment
Description: Standard medical treatment
Study NCT05550103 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical treatment
Description: Standard medical treatment
Study NCT05143970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB
Description: Part I-Dose escalation Patients will receive IPH5301 alone on day 1 (Week 1). Treatment will be administered every 2 weeks until progression or unacceptable toxicity or other reasons requiring treatment discon-tinuation, for a maximum duration of 12 months.~Part II- Expansion cohort Patients will receive IPH5301 at a recommended dose (RP2D) or a next lower dose (RP2D-1)in combination with trastuzumab and paclitaxel, at day 1 and every 2 weeks up to 6 cycles of paclitaxel. The RP2D dose will not exceed the designated maximum tolerated dose (MTD).
Study NCT06241027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nerve flossing technique
Description: The nerve flossing technique will be perform actively with the participant sitting on the chair. The participant flexed the knee of the target lower extremity backward beside the chair as far back as possible and flexed the neck at the same time, holding both the flexed knee and neck in thisposition for 5 seconds. The participant in turn extended the neck and knee of the target lower extremity, abducted and flexed the hip until pain will feel and did not push beyond that point. This extended position will be hold for 5 seconds.
Study NCT06241027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release
Description: Myofascial release therapy involved the application of a low load, long duration stretch along the line of maximal fascial restriction. Pressure will be applied directly on the skin toward the direction of restriction until resistance of the tissue barrier will felt, Once found , the collagenous barrier will engaged for 90-120 seconds without sliding over the skin or forcing the tissues until the fascia complex started to yield and a sensation of softening will achieved.This stage will be repeated up to 5 times for new barrier until the sensation of tissue restriction during stretching became weaker.
Study NCT05124665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: The intervention to be evaluated in this study is a multidimensional, socio-behavioral Norming intervention. The various components of this intervention are designed to harness household dynamics and prosocial inclinations to encourage individuals to accept the HIV testing invitation. Each component is briefly described in the arm description.
Study NCT06201000 — intervention group
Intervention type: DRUG
Intervention: SGLT2 inhibitors (Dapagliflozin and Empagliflozin)
Description: 10 mg of dapagliflozin or empagliflozin
Study NCT05382026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation during a 6 month resistance training program
Description: 1% chocolate milk
Study NCT05382026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional supplementation during a 6 month resistance training program
Description: Pea-based beverage
Study NCT05382026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional supplementation during a 6 month resistance training program
Description: Maltodextrin placebo
Study NCT06231303 — intervention group
Intervention type: GENETIC
Intervention: DNA extraction and PCR amplification
Description: Microbial community genomic DNA extraction from fecal samples will be done using extraction kit in accordance with the manufacturer's instructions. The DNA extract will be checked on a 1% agarose gel, and the DNA concentration and purity will be determined using the NanoDrop 2000 UV-vis spectrophotometer.~The hyper-variable region V3-V4 of the bacterial 16S rRNA gene will be amplified with the primer pair 338F (ACTCCTACGGGAGGCAGCAG) and 806R (GGACTACHVGGGTATCTAAT) on a PCR thermocycler. PCR amplification of the 16S rRNA gene will performed as follows:~Initial denaturation at 95 ℃ for 3 min. 27 cycles of denaturing at 95 ℃ for 30 s, annealing at 55 ℃ for 30 s, and extension at 72 ℃ for 45 s.~Final extension step at 72 ℃ for 10 min and incubation at 10 ℃. The PCR product will then be used to quantify different bacterial species in stool samples of patients and controls using real time PCR.
Study NCT06132607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preoperative 3D lung reconstruction created with open-source software
Description: Preoperative 3D lung reconstruction created with open-source software 3D Slicer
Study NCT05489315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positioning with peanut ball
Description: If participants are randomly selected to receive a peanut ball, the intent is for the patient to remain on the peanut ball during their labor progression.
Study NCT05489315 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional positioning
Description: If participants are randomly selected to NOT receive a peanut ball, the intent is for the patient to undergo traditional positioning/use wedge pillows during their labor progression.
Study NCT04965194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae plane block
Description: Superficial probe will be placed 2-3 cm lateral to the spine using a sagittal approach at the level of T8. After identification of erector spinae muscle and transverse processes, the needle will be inserted deeply into the erector spinae muscle. Correct position of the needle tip is confirmed with administration of 0.5-1 ml of local anesthetic (LA), and 20 ml of 0.25% bupivacaine will be administered to perform ESP block. LA spread to both cranial and caudal directions will be seen.
Study NCT04965194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum plane block
Description: A curved array transducer for the transmuscular QL (TQL) nerve block is placed in the axial plane on the patient's flank just cranial to the iliac crest. The shamrock sign is visualized: The transverse process of vertebra L4 is the stem, whereas the erector spinae posteriorly, QL laterally, and psoas major anteriorly represents the three leaves of the trefoil. The target for injection is the fascial plane between the QL and psoas major muscles. The needle is inserted using an in-plane technique from the posterior end of the transducer through the QL muscle. The injectate (20ml of bupivacaine 0.25%) should ideally spread from the injection site inside the fascial plane between the QL and psoas major muscles to the thoracic paravertebral space with a goal to accomplish segmental somatic and visceral analgesia from T4 to L1.
Study NCT04965194 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients received no regional block
Study NCT05669079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: 15 mg/m2 daily intravenously for consecutive 3 days
Study NCT05669079 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord blood
Description: MNC ≥ 3\*108 cells; HLA compatibility ≥ 5/6
Study NCT05669079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor
Description: Granulocyte-colony stimulating factor will be used when absolute neutrophil count ≤ 1.5 × 109/L
Study NCT05669079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte-colony stimulating factor
Description: Granulocyte-colony stimulating factor will be used when absolute neutrophil count ≤ 1.5 × 109/L
Study NCT05669079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human thrombopoietin / thrombopoietin receptor agonist
Description: Recombinant human thrombopoietin or thrombopoietin receptor agonist will be used when platelet count ≤ 30 × 109/L
Study NCT05669079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human thrombopoietin / thrombopoietin receptor agonist
Description: Recombinant human thrombopoietin or thrombopoietin receptor agonist will be used when platelet count ≤ 30 × 109/L
Study NCT05669079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Description: Recombinant human erythropoietin will be used when hemoglobin ≤ 85 g/L
Study NCT05669079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human erythropoietin
Description: Recombinant human erythropoietin will be used when hemoglobin ≤ 85 g/L
Study NCT05934292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide Decanoate
Description: Single oral dose
Study NCT06221696 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active Fiber Supplement Group
Description: Three daily packets of active fiber supplement (each containing 1g of glucomannan, 1g of inulin, and 3g of psyllium), taken 30 minutes before each main meal. The supplement is provided by S.Lab (Soloways), LLC.
Study NCT06221696 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Three daily packets of placebo powder, taken 30 minutes before each main meal.
Study NCT04702087 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OLEP
Description: omega 3 (500 mg), leucine (2,5 g), probiotic Lactobacillus paracasei PS23
Study NCT04702087 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isocaloric formula
Study NCT05729334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinicgram Euclides
Description: Clinicgram Euclides is a software that allows automated calculation of the area of skin lesions using a mobile device. Three different photographs will be taken of the subject's skin lesion. The area of the skin lesion will be calculated using the photograph of the skin lesion, and:~* for EUCLIDES 2D, an external marker. The investigator will outline the skin lesion and the external marker in the photograph prior to the calculation of the skin lesion area.~* for EUCLIDES 3D, a two reference points selected by the investigator.
Study NCT05552820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum Electroacupuncture
Description: Acupoints: Cuanzhu (BL2), Taiyang (EX-HN5), Sibai (ST1), Sizhukong (TE23), Baihui (GV20), Fengchi (GB20), Hegu (LI4), Zusanli (ST36), Guangming (GB23), Sanyinjiao (SP6), and Taichong (LR3). All acupoints will be taken bilaterally, except Baihui (GV20). The subject is placed in the supine position with eyes close. After routine sterilization, the sterile polyethylene cylindrical needle pad will be adhered to the acupoints. Then, the sterile acupuncture needles (0.25 mm×0.40 mm, Hwato brand, China.) will be inserted into the skin through the needle pad. Twirling and lifting-thrusting manipulations will be performed on the acupoints until Deqi is reported by the subject. Two pairs of electrodes will be connected at the needle handles on BL2 and EX-HN5 with a 2 Hz, continuous-wave electro-stimulation provided by the electroacupuncture apparatus (SDZ-Ⅲ type, Hwato brand, China). The pulse amplitude is about 1-2 mA.
Study NCT05552820 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Electroacupuncture
Description: Sham acupoints: SA1(1 cm above BL2), SA2 (1 cm above SJ23)，SA3 (1 cm above EX-HN5), SA4 (1 cm lateral to ST2), SA5 (the midpoint of the line between GV20 and right EX-HN1), SA6 (the midpoint of the line between GB20 and SJ16), SA7 (1 cm lateral to LI4), SA8 (the midpoint of the line between ST36 and GB34), SA9 (the midpoint of the line between GB37 and BL58), SA10 (1 cm backward to SP6), SA11 (the midpoint of the line between LR3 and SP4). After routine sterilization, placebo needles will be used (Streitberger, Asia-med GmbH). The tingling sensation produced when the Streitberger needle is fixed on the skin causes the subject to believe that the needle is piercing the skin, simulating a skin puncture. The electric stimulator is applied to bilateral SA1 and SA3 with no current output. The exterior appearance, indicator light, prompt tone of the sham device, and stimulation parameters are all indistinguishable from the normal one.
Study NCT03856437 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV vaccination messages
Description: Digital multimedia messages consisting of text and imagery conveying the benefits of being vaccinated against HPV, the costs of not being vaccinated against HPV, or neither benefits or costs but simply a call for action.
Study NCT03856437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV vaccination messages
Description: Digital multimedia messages consisting of text and imagery conveying the benefits of being vaccinated against HPV, the costs of not being vaccinated against HPV, or neither benefits or costs but simply a call for action.
Study NCT06310512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured drug therapy management
Description: Interventions mainly included (1) information collection, clinical assessment, and evaluation of medication regimens; (2) identification of and intervention for medication-related problems; (3) pharmacy instruction and education, and development of personal medication lists; and (4) follow-up and reassessment
Study NCT05114304 — intervention group
Intervention type: OTHER
Intervention: Evaluation of co-morbid psychiatric disorders
Description: Added scales :~* Mini Internationnal Neuropsychiatric Interview~* Fagerström test~* DSM-5 Scale~Additional dosage : - a urine sample will be taken to evaluate the presence of tobacco and nicotine breakdown products and the presence of various toxics~Expired carbon monoxide for patients using nicotine substitutes
Study NCT04583813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Empagliflozin 10 mg oral tablet, once daily, for 24 months
Study NCT06437015 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy
Description: patient's unaffected hand is tied with a triangular bandage or splint and the patient asks to perform the exercise through the affected hand. for up to 6 hours a day for 5days week /4 weeks and the patient nonparetic arm restrained from the use by having the patient placing a mitt on the hand or a sling on the unaffected hand, forcing the use of the affected limb to promote purposeful movements when performing functional tasks.
Study NCT06437015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mirror Therapy
Description: In this group training was given for 45min a day for 5 days a week for 4 weeks. Mirror box which was of 18×24inch \[was placed on the learning table and exercises were carried out by the patient looking into the mirror where an unaffected limb is placed in front of the mirror, through looking into the mirror patient assumes the reflection of the unaffected limb as the paretic limb. Exercises performed were hand opening and closing, wrist extension and flexion, squeezing, opposition, the calculation
Study NCT04583813 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Empagliflozin matching placebo, once daily, for 24 months
Study NCT05737394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic-guided TAP Block
Description: Laparoscopically-assisted placement of block
Study NCT05737394 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided TAP Block
Description: Ultrasound-assisted placement of block
Study NCT06425822 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Left atrial electroanatomical mapping
Description: Left atrial electroanatomical mapping (substrate and functional mapping)
Study NCT04937881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Description: Daily DOT fixed dose combination of 200 mg emtricitabine (FTC) and 25 mg tenofovir alafenamide (TAF)
Study NCT04937881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: Daily DOT fixed dose combination of 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF)
Study NCT04747470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-3583
Description: Administered as an intravenous (IV) infusion
Study NCT06415227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vericiguat
Description: The target dose of vericiguat is 10 milligrams once daily, which will be started at 2.5mg once daily and uptitrated every two weeks to reach the target dose. Dose modification will depend on mean sitting systolic blood pressure and the absence of symptoms indicative of hypotension. The intention of the protocol is to reach and maintain the target study drug dose after completion of uptitration. If the dose is temporarily interrupted, then resumption of study drug treatment and continued uptitration will be considered at any subsequent visit when the investigator feels it is medically appropriate. Vericiguat will be taken orally once daily at about the same time.
Study NCT06415227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat
Description: The target dose of vericiguat is 10 milligrams once daily, which will be started at 2.5mg once daily and uptitrated every two weeks to reach the target dose. Dose modification will depend on mean sitting systolic blood pressure and the absence of symptoms indicative of hypotension. The intention of the protocol is to reach and maintain the target study drug dose after completion of uptitration. If the dose is temporarily interrupted, then resumption of study drug treatment and continued uptitration will be considered at any subsequent visit when the investigator feels it is medically appropriate. Vericiguat will be taken orally once daily at about the same time.
Study NCT05701696 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Central sensitization inventory
Description: Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.
Study NCT05701696 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Widespread pain index
Description: Total the number of painful body areas
Study NCT05701696 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Symptom severity scale
Description: The sum of the fatigue, waking unrefreshed and cognitive symptoms and the extent of somatic symptoms
Study NCT05701696 — intervention group
Intervention type: OTHER
Intervention: Fibromyalgia impact questionnaire
Description: A tool to assess health status in fibromyalgia
Study NCT05701696 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hospital Anxiety and Depression Scale
Description: An instrument for detecting depression and anxiety
Study NCT05701696 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Self-Leeds Assessment of Neuropathic Symptoms and Signs
Description: An instrument used to identify pain of neuropathic origin
Study NCT05697900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creatine Monohydrate
Description: The CrM group supplemented the diet with five grams of micronized creatine monohydrate per day for eight weeks. The CrM supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).
Study NCT05697900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo group intakes five grams of maltodextrin daily throughout the study. The placebo supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).
Study NCT05697900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Hydrochloride
Description: The Cr-HCl group supplemented the diet with five grams of micronized creatine monohydrate per day for eight weeks. The Cr-HCl supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).